Cosmos Health Earnings & Forecasts

Cosmos Health (COSM) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Aug 18, 2026	$-0.10	$0.01	-1100.0 %
Q1	May 21, 2026	$-0.06	$-0.01	-500.0 %
Q4	Apr 15, 2026	$-0.04	$-0.05	20.0 %
Q4	Apr 16, 2025	$-0.45	$-0.11	-309.1 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Aug 18, 2026	$18.99M	$19.42M	-2.24 %
Q1	May 21, 2026	$17.93M	$21.89M	-18.1 %
Q4	Apr 15, 2026	$19.70M	$19.57M	0.66 %
Q4	Apr 16, 2025	$14.22M	$14.50M	-1.90 %

Cosmos Health Guidance

Cosmos Health (COSM) は、9 3, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高をの範囲と予想しています。

以前のガイダンスと比較して、Cosmos Healthは売上高予測を以前の範囲である引き上げから$19.4M - $19.4Mに引き上げました。

Cosmos Healthは、10から9 18, 2024の間に9 3, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 4 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.01	$-0.01	$-0.05	—
Actual	$-0.10	$-0.06	$-0.04	$-0.02
Surprise	-1100.0%	-500.0%	+20.0%	—
Revenue
Estimate	$19.4M	$21.9M	$19.6M	—
Actual	$19.0M	$17.9M	$19.7M	$17.1M
Surprise	-2.24%	-18.1%	+0.66%	—

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.05	$-0.03	$0.01
Revenue
Consensus	$20.9M	$23.0M	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Cosmos Health Reaffirms FY 2029 Guidance, Expects $200.60M Revenue, $71.20M Gross Profit, $31M Net Income, $44.20M Adjusted EBITDA

Benzinga Newsdesk

PRO
Cosmos Health Says It Projects Oliv18 To Generate Over $6M In Incremental Annual U.S. Revenue Within 12 To 18 Months

Benzinga Newsdesk

PRO
Cosmos Health Q2 EPS $(0.10) Misses $0.01 Estimate, Sales $18.986M Miss $19.420M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported

Benzinga Newsdesk

PRO
Cosmos Health Reports Preliminary Q2 Revenue Of $19.4M, Up 31.5% YoY, H1 Revenue Of $37.3M, Up ~31% YoY

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46

Benzinga Newsdesk

PRO
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a

Benzinga Newsdesk

PRO
Cosmos Health Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $17.928M Miss $21.893M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the

Benzinga Newsdesk

Cosmos Health Inc